日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research.

开发和表征三种新型FGFR抑制剂耐药宫颈癌细胞系,以推动宫颈癌研究

Bou Antoun Nauf, Afshan Mahmood Hiba-Tun-Noor, Walker Anthony J, Modjtahedi Helmout, Grose Richard P, Chioni Athina-Myrto

CHCHD4 Oxidoreductase Activity: A Comprehensive Analysis of the Molecular, Functional, and Structural Properties of Its Redox-Regulated Substrates

CHCHD4氧化还原酶活性:对其氧化还原调控底物的分子、功能和结构特性的综合分析

Balasco, Nicole; Modjtahedi, Nazanine; Monti, Alessandra; Ruvo, Menotti; Vitagliano, Luigi; Doti, Nunzianna

The Co-Expression and Cellular Location of HER Family Members, EGFRvIII, Putative Cancer Stem Cell Biomarkers CD44 and CD109 in Patients with Glioblastoma, and Their Impacts on Prognosis

HER家族成员、EGFRvIII、假定癌症干细胞生物标志物CD44和CD109在胶质母细胞瘤患者中的共表达和细胞定位及其对预后的影响

Mulliqi, Ermira; Khelwatty, Said; Bagwan, Izhar; Kamaludin, Ahmad; Morgan, Anna; Long, Natalie; Ashkan, Keyoumars; Modjtahedi, Helmout

Results of a New Virtual Program for Patients Overdue for Diabetic Retinopathy Evaluation

一项针对逾期未进行糖尿病视网膜病变评估患者的新型虚拟项目的结果

Moore, Shannan G; Chen, Daniel X; Sharma, Munish; Hedayi, Rudy; Fong, Donald S; Modjtahedi, Bobeck S

Co-expression of HER2/EGFRvIII/CD44 and Claudin 18.2/CD109 as Novel Prognostic Indicators in Stomach Adenocarcinoma.

HER2/EGFRvIII/CD44 和 Claudin 18.2/CD109 共表达作为胃腺癌的新型预后指标

Al Janaby Tina, Khelwatty Said, Bagwan Izhar, Abbassi-Ghadi Nima, Modjtahedi Helmout

Eye Care in Federally Qualified Health Centers

联邦认证医疗中心的眼科护理

Woodward, Maria A; Hicks, Patrice M; Harris-Nwanyanwu, Kristen; Modjtahedi, Bobeck; Chan, R V Paul; Vogt, Emily L; Lu, Ming-Chen; Newman-Casey, Paula Anne

Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma

EGFRvIII 的表达及其与野生型 EGFR 的共表达,或推定的癌症干细胞生物标志物 CD44 或 EpCAM 与肝细胞癌患者的预后较差相关

Ozlem Sherif, Said A Khelwatty, Izhar Bagwan, Alan M Seddon, Angus Dalgleish, Satvinder Mudan, Helmout Modjtahedi

Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells

Neratinib 与 Palbociclib 或 Miransertib 联合治疗脑癌细胞的协同作用

Ermira Mulliqi, Said Khelwatty, Anna Morgan, Keyoumars Ashkan, Helmout Modjtahedi

The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells

阿法替尼与达沙替尼或 Miransertib 联合使用可协同抑制胃癌细胞生长

Tina Al-Janaby, Narmin Nahi, Alan Seddon, Izhar Bagwan, Said Khelwatty, Helmout Modjtahedi

Glycemic Control in Patients After Initiation of Treatment for Vision-Threatening Diabetic Retinopathy

视力威胁性糖尿病视网膜病变患者开始治疗后的血糖控制

Moore, Shannan; Wu, Jun; Pio, Jose; Modjtahedi, Bobeck S